Physician profile
Sunhee Kim
NPI 1073920385
$3,667.98
in general payments reported to CMS, 2019-2025
39 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $121 · 2023: $268 · 2024: $1,233 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $472.77 | 2021-2024 | Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $447.93 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Janssen Biotech, INC. | $223.49 | 2023-2025 | Talvey, Tecvayli, Rybrevant |
| Incyte Corporation | $222.14 | 2021-2025 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $217.73 | 2023-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $167.24 | 2023-2025 | Ninlaro, Fruzaqla, Vpriv |
| Genzyme Corporation | $147.35 | 2024-2025 | |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Abbott Laboratories | $121.21 | 2022 | |
| Genentech USA, INC. | $112.18 | 2024-2025 | Tecentriq Hybreza, Tecentriq, Itovebi |
| Alexion Pharmaceuticals, INC. | $89.32 | 2024-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $88.78 | 2023-2025 | Tazverik, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $88.27 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $87.69 | 2024-2025 | Rybrevant |
| Pharmacosmos Therapeutics INC. | $84.38 | 2024-2025 | Monoferric, Cosela |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $82.31 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.29 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Kyowa Kirin, INC. | $70.68 | 2024-2025 | Poteligeo |
| Agios Pharmaceuticals, INC. | $70.23 | 2024-2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $61.06 | 2024-2025 | Besremi |
| Geron Corporation | $59.46 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $51.99 | 2023-2025 | Qinlock, Romvimza |
| Tersera Therapeutics LLC | $51.33 | 2025 | Zoladex |
| Karyopharm Therapeutics INC. | $47.73 | 2024 | Xpovio |
| Stemline Therapeutics INC. | $43.63 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $38.91 | 2025 | Revuforj |
| Alnylam Pharmaceuticals INC. | $37.20 | 2025 | Amvuttra |
| Puma Biotechnology, INC. | $31.79 | 2024-2025 | |
| Blueprint Medicines Corporation | $30.14 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.30 | 2025 | |
| Genmab U.S., INC. | $25.94 | 2025 | Epkinly |
| Lilly USA, LLC | $25.89 | 2025 | Jaypirca, Verzenio |
| Eisai INC. | $23.25 | 2024 | |
| Novocure INC. | $21.41 | 2025 | Optune Gio |
| Coherus Oncology, INC. | $18.95 | 2025 | Udenyca, Loqtorzi |
| Beone Medicines USA, INC. | $18.84 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $18.40 | 2024 | |
| Melinta Therapeutics, LLC | $18.19 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Pharmaceuticals, INC | $17.58 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunhee Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.